...
mrk-img

Merck & Company Inc, Common Stock

MRK

NYQ

$125.77

+$1.52

(1.22%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$318.55B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
138.82
Volume info-icon
This is the total number of shares traded during the most recent trading day.
6.84M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
10.56M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
2.48%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$97.23 L
$134.63 H
$125.77

About Merck & Company Inc, Common Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameMRKSectorS&P500
1-Week Return-1.56%-0.78%-1.28%
1-Month Return-3.01%0.89%1.37%
3-Month Return0.59%6.29%12.01%
6-Month Return7.09%6.29%15.36%
1-Year Return21.87%12.68%23.24%
3-Year Return78.58%21.13%36.17%
5-Year Return88.51%74.73%101.78%
10-Year Return208.29%182.71%236.91%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue46.84B47.99B48.70B59.28B59.87B[{"date":"2019-12-31","value":78.23,"profit":true},{"date":"2020-12-31","value":80.16,"profit":true},{"date":"2021-12-31","value":81.35,"profit":true},{"date":"2022-12-31","value":99.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue14.11B15.48B13.63B17.41B15.98B[{"date":"2019-12-31","value":81.05,"profit":true},{"date":"2020-12-31","value":88.94,"profit":true},{"date":"2021-12-31","value":78.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.76,"profit":true}]
Gross Profit32.73B32.51B35.08B41.87B43.89B[{"date":"2019-12-31","value":74.56,"profit":true},{"date":"2020-12-31","value":74.06,"profit":true},{"date":"2021-12-31","value":79.92,"profit":true},{"date":"2022-12-31","value":95.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin69.87%67.74%72.02%70.63%73.31%[{"date":"2019-12-31","value":95.3,"profit":true},{"date":"2020-12-31","value":92.39,"profit":true},{"date":"2021-12-31","value":98.24,"profit":true},{"date":"2022-12-31","value":96.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses20.49B24.03B21.88B23.59B40.91B[{"date":"2019-12-31","value":50.08,"profit":true},{"date":"2020-12-31","value":58.73,"profit":true},{"date":"2021-12-31","value":53.48,"profit":true},{"date":"2022-12-31","value":57.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income9.23B5.44B10.65B14.71B2.98B[{"date":"2019-12-31","value":62.73,"profit":true},{"date":"2020-12-31","value":36.95,"profit":true},{"date":"2021-12-31","value":72.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.27,"profit":true}]
Total Non-Operating Income/Expense1.62B2.58B2.46B929.00M(1.77B)[{"date":"2019-12-31","value":62.64,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.35,"profit":true},{"date":"2022-12-31","value":35.97,"profit":true},{"date":"2023-12-31","value":-68.68,"profit":false}]
Pre-Tax Income11.46B8.79B13.88B16.44B1.89B[{"date":"2019-12-31","value":69.72,"profit":true},{"date":"2020-12-31","value":53.46,"profit":true},{"date":"2021-12-31","value":84.4,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":11.49,"profit":true}]
Income Taxes1.69B1.71B1.52B1.92B1.51B[{"date":"2019-12-31","value":87.96,"profit":true},{"date":"2020-12-31","value":89.1,"profit":true},{"date":"2021-12-31","value":79.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.83,"profit":true}]
Income After Taxes9.78B7.08B12.36B14.53B377.00M[{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.6,"profit":true}]
Income From Continuous Operations9.78B7.08B12.36B14.53B4.62B[{"date":"2019-12-31","value":67.31,"profit":true},{"date":"2020-12-31","value":48.75,"profit":true},{"date":"2021-12-31","value":85.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.81,"profit":true}]
Income From Discontinued Operations704.00M704.00M704.00M--[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income9.84B7.07B13.05B14.52B365.00M[{"date":"2019-12-31","value":67.79,"profit":true},{"date":"2020-12-31","value":48.67,"profit":true},{"date":"2021-12-31","value":89.88,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.51,"profit":true}]
EPS (Diluted)5.195.936.267.481.50[{"date":"2019-12-31","value":69.39,"profit":true},{"date":"2020-12-31","value":79.28,"profit":true},{"date":"2021-12-31","value":83.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":20.05,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MRK
Current Ratio 1.25
Quick Ratio 0.99

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MRK
ROA (LTM) 10.26%
ROE (LTM) 5.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MRK
Debt Ratio Lower is generally better. Negative is bad. 0.62
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.38
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 2.62

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MRK
Trailing PE 139.61
Forward PE 14.68
P/S (TTM) 5.30
P/B 8.48
Price/FCF NM
EV/R 5.76
EV/Ebitda 50.16
PEG NM

News

BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer | BGNE Stock News

BeiGene appoints Merck veteran Aaron Rosenberg as CFO, bolstering its position as a top 15 global oncology innovator. Learn how this strategic move supports BeiGene''s growth and leadership in cancer treatments.

18 Jul, 2024 a 10:30 am Stock Titan

Merck Begins Commercial Production of First GMP-Compliant Manufacturing Line for Cell Culture Media in China

… in-house formulation knowledge, Merck designs robust custom CCM for … processes. “This investment further expands Merck ’s footprint and capabilities in … lines, bioreactors, filters, resins, chromatographic, pharmaceutical raw materials, and excipients. Its …

18 Jul, 2024 a 10:02 am EIN News Pharmaceuticals

Merck To Acquire Unity-SC

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Merck said it plans to acquire Unity-SC, a provider of metrology and inspection instrumentation for the semiconductor industry. The transaction amount includes…

18 Jul, 2024 a 8:30 am Finanz Nachrichten

Column: Merck defeats appeal by nearly 1,200 shingles vaccine plaintiffs

Merck has beaten back an appeal by nearly 1,200 plaintiffs who claimed their cases were improperly dismissed by the federal judge overseeing mass torts litigation over its Zostavax shingles vaccine.

17 Jul, 2024 a 8:49 pm Reuters

Brianne Gardner''s Past Picks: Canadian Natural Resources, Tourmaline Oil, and Merck & Co.

Brianne Gardner, senior wealth manager at Velocity Investment Partners, Raymond James, discusses his past picks: Canadian Natural Resources, Tourmaline Oil, and Merck & Co.

17 Jul, 2024 a 4:42 pm BNN Bloomberg

3 Top Cancer Treatment Stocks to Buy Now

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck’s (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year. And even back in 2018, its fourth year on the market, the drug was responsible for putting $7.2 billion in Merck’s coffers. Many new types of cancer treatments are being developed, including personalized cancer vaccines, and precision oncology treatments. But very few treatments have the potential to be the next Keytruda. In this column on cancer treatment stocks, I will identify two companies with drugs that I think could fit the bill. I will also profile a company that has developed a blood test which successfully detects many types of the disease in the early stages. By doing so, it can save millions of lives. Grail ( GRAL ) Source: JHVEPhoto / Shutterstock.com Grail’s (NASDAQ: GRAL ) Galleri blood test can determine whether individuals have over 50 types of cancer.

17 Jul, 2024 a 10:30 am InvestorPlace

Merck & Co., Inc.: Here for Good: Merck''s Steadfast Commitment to Health Equity

How one employee''s upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a l…

16 Jul, 2024 a 10:02 pm Finanz Nachrichten

Here for Good: Merck''s Steadfast Commitment to Health Equity

How one employee''s upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work … Jetzt den vollständigen Artikel lesen

16 Jul, 2024 a 8:52 pm Wallstreet:Online

3 Biotech Stocks to Buy in Case of Another Pandemic

While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics. This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic. That being said, the opportunity always exists for biotech stocks during times of health crisis. Especially vaccines and prophylactic measures, which could turn lucrative for investors, due to investing in early on a company whose products become critical to a worldwide solution. To determine the potential of these companies’ treatments, we will look at their scalability, and the disease they’re intended to address. As such here are three biotech stocks to watch for the future of global health. Moderna (MRNA) Source: Carlos l Vives / Shutterstock.com Moderna (NASDAQ: MRNA ) is the vaccine producer focused on using the mRNA technology. Yet, what is exceptionally exciting about this technology is how readily it can be applied to other types of respiratory viruses beyond the one that caused the Covid-19 pandemic.

16 Jul, 2024 a 5:33 pm InvestorPlace

FAQs

What is Merck & Company Inc share price today?

Merck & Company Inc (MRK) share price today is $125.77

Can Indians buy Merck & Company Inc shares?

Yes, Indians can buy shares of Merck & Company Inc (MRK) on Vested. To buy Merck & Company Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Merck & Company Inc be purchased?

Yes, you can purchase fractional shares of Merck & Company Inc (MRK) via the Vested app. You can start investing in Merck & Company Inc (MRK) with a minimum investment of $1.

How to invest in Merck & Company Inc shares from India?

You can invest in shares of Merck & Company Inc (MRK) via Vested in three simple steps:

  • Click on Sign Up or Invest in MRK stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Merck & Company Inc shares
What is Merck & Company Inc 52-week high and low stock price?

The 52-week high price of Merck & Company Inc (MRK) is $134.63. The 52-week low price of Merck & Company Inc (MRK) is $97.23.

What is Merck & Company Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Merck & Company Inc (MRK) is 138.82

What is Merck & Company Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Merck & Company Inc (MRK) is 8.48

What is Merck & Company Inc dividend yield?

The dividend yield of Merck & Company Inc (MRK) is 2.48%

What is the Market Cap of Merck & Company Inc?

The market capitalization of Merck & Company Inc (MRK) is $318.55B

What is Merck & Company Inc’s stock symbol?

The stock symbol (or ticker) of Merck & Company Inc is MRK

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top